Listed by the USPTO as ZAHORIK, AMANDA MARY
Tech Center 1600 • Art Units: 1635 1636 1645 1653 1654 1674
This examiner grants 58% of resolved cases
ZAHORIK, AMANDA MARY is a USPTO patent examiner in tech center 1600 and art unit 1635. The record shows 84 resolved cases, a 58.3% allowance rate, and a median of 1318 days to allowance. The allowance figure indicates that more than half of the recorded resolved cases reached allowance, while the pendency figure identifies a lengthy measured prosecution interval.
The interview lift is 49.3%, showing a pronounced positive association between interviews and allowance outcomes. Alnylam Pharmaceuticals Inc., University of Florida Research Foundation Inc., and Intellia Therapeutics Inc. are the listed companies. The listed firms are WENDEROTH, LIND & PONACK, L.L.P., Bayramoglu Law Offices LLC, and BENESCH, FRIEDLANDER, COPLAN & ARONOFF LLP. Interview preparation may warrant particular attention for matters in art unit 1635.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17228298 | ENGINEERED RECEPTOR/LIGAND SYSTEM FOR DELIVERY OF THERAPEUTIC AGENTS | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18557218 | LIPID NANOMATERIALS AND USES THEREOF | Non-Final OA | Ohio State Innovation Foundation |
| 18488316 | HSD17B13 VARIANTS AND USES THEREOF | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17266995 | METHODS FOR ASSESSING INTEGRATED NUCLEIC ACIDS | Final Rejection | Juno Therapeutics, Inc. |
| 17433639 | CIRCULAR POLYRIBONUCLEOTIDES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Final Rejection | Flagship Pioneering Innovations VI, LLC |
| 18572654 | METHODS OF DETERMINING RESPONSIVENESS TO CHEMOTHERAPEUTIC COMPOUNDS FOR CANCER THERAPY | Non-Final OA | President and Fellows of Harvard College |
| 17802751 | ACTIVATION OF LYTIC GENES IN CANCER CELLS | Non-Final OA | The Chinese University of Hong Kong |
| 18674830 | DEVICES, SYSTEMS, KITS, AND METHODS FOR ON-FARM DETECTION OF CONTAMINATION | Non-Final OA | Purdue Research Foundation |
| 18667652 | NON-INVASIVE SITE-SPECIFIC MEASUREMENT OF TRANSGENE EXPRESSION IN THE BRAIN | Non-Final OA | William Marsh Rice University |
| 18288887 | PREVENTION OR TREATMENT OF MYOPATHY USING MIR-33B INHIBITOR | Final Rejection | OSAKA UNIVERSITY |
| 17494047 | COMPOSITIONS AND METHODS FOR RAPID AND DYNAMIC FLUX CONTROL USING SYNTHETIC METABOLIC VALVES | Non-Final OA | DUKE UNIVERSITY |
| 18275146 | METHODS AND COMPOSITIONS FOR REGENERATING HAIR CELLS IN THE INNER EAR OF ADULT MAMMALS | Final Rejection | Massachusetts Eye and Ear Infirmary |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy58.3% of resolved applications examined by Amanda Mary Zahorik were allowed (84 resolved cases), compared with 51.6% across Art Unit 1635 over the last five years.
This examiner's interview lift is +49.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Amanda Mary Zahorik took 1,318 days on average from filing to allowance.
Amanda Mary Zahorik examines applications in Art Unit 1635 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
